Lantern Pharma Files 2024 10-K
Ticker: LTRN · Form: 10-K · Filed: Mar 27, 2025 · CIK: 1763950
| Field | Detail |
|---|---|
| Company | Lantern Pharma Inc. (LTRN) |
| Form Type | 10-K |
| Filed Date | Mar 27, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, annual-report, pharmaceuticals
TL;DR
Lantern Pharma dropped its 2024 10-K. Financials look detailed.
AI Summary
Lantern Pharma Inc. filed its 2024 10-K on March 27, 2025, reporting on its fiscal year ending December 31, 2024. The company, based in Dallas, Texas, operates in the pharmaceutical preparations sector. Key financial data for the periods ending December 31, 2024, and 2023, including preferred stock, common stock, additional paid-in capital, accumulated other comprehensive income, and retained earnings, are detailed in the filing.
Why It Matters
This filing provides investors with a comprehensive overview of Lantern Pharma's financial performance and position for the fiscal year 2024, crucial for understanding the company's health and future prospects.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Lantern Pharma faces inherent risks related to drug development, regulatory approvals, and market competition, which are typical for the industry.
Key Numbers
- 2024-12-31 — Fiscal Year End (The end date of the reporting period for the 10-K.)
- 2023-12-31 — Prior Fiscal Year End (The end date of the previous reporting period.)
- 2025-03-27 — Filing Date (The date the 10-K was officially submitted to the SEC.)
Key Players & Entities
- Lantern Pharma Inc. (company) — Filer of the 10-K
- 20250327 (date) — Filing date of the 10-K
- 20241231 (date) — Fiscal year end for the report
- Dallas, TX (location) — Company headquarters
- PHARMACEUTICAL PREPARATIONS [2834] (industry) — Company's Standard Industrial Classification
FAQ
What were Lantern Pharma's total revenues for the fiscal year ended December 31, 2024?
The provided text does not contain specific revenue figures for the fiscal year ended December 31, 2024.
What is the company's net income or loss for the fiscal year ended December 31, 2024?
The filing excerpt does not specify the net income or loss for the fiscal year ended December 31, 2024.
What were the significant changes in 'Additional Paid-In Capital' between December 31, 2023, and December 31, 2024?
While the filing indicates 'AdditionalPaidInCapitalMember' for both 2023 and 2024, specific change amounts are not detailed in this excerpt.
Does the filing mention any new drug development pipelines or clinical trial updates for 2024?
This excerpt focuses on company identification and financial statement periods and does not include details on drug development or clinical trials.
What is Lantern Pharma's current cash and cash equivalents balance as of December 31, 2024?
The provided text does not include information on the company's cash and cash equivalents.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 27, 2025 regarding Lantern Pharma Inc. (LTRN).